135 related articles for article (PubMed ID: 38401774)
41. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
42. A Head-to-head Comparison of De Novo Sirolimus or Everolimus Plus Reduced-dose Tacrolimus in Kidney Transplant Recipients: A Prospective and Randomized Trial.
Toniato de Rezende Freschi J; Cristelli MP; Viana LA; Ficher KN; Nakamura MR; Proença H; Dreige YC; de Marco R; de Lima MG; Foresto RD; Aguiar WF; Medina-Pestana J; Tedesco-Silva H
Transplantation; 2024 Jan; 108(1):261-275. PubMed ID: 37525373
[TBL] [Abstract][Full Text] [Related]
43. Drug targets in cytomegalovirus infection.
Andrei G; De Clercq E; Snoeck R
Infect Disord Drug Targets; 2009 Apr; 9(2):201-22. PubMed ID: 19275707
[TBL] [Abstract][Full Text] [Related]
44.
Krueger MB; Bonifacius A; Dragon AC; Santamorena MM; Nashan B; Taubert R; Kalinke U; Maecker-Kolhoff B; Blasczyk R; Eiz-Vesper B
Transpl Int; 2024; 37():12720. PubMed ID: 38655204
[TBL] [Abstract][Full Text] [Related]
45. Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients.
Hasegawa J; Hatakeyama S; Wakai S; Omoto K; Okumi M; Tanabe K; Mieno M; Shirakawa H
Int J Infect Dis; 2017 Dec; 65():50-56. PubMed ID: 28986314
[TBL] [Abstract][Full Text] [Related]
46. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report.
Kobashigawa JA; Miller LW; Russell SD; Ewald GA; Zucker MJ; Goldberg LR; Eisen HJ; Salm K; Tolzman D; Gao J; Fitzsimmons W; First R;
Am J Transplant; 2006 Jun; 6(6):1377-86. PubMed ID: 16686761
[TBL] [Abstract][Full Text] [Related]
47. Reconstitution of Human Cytomegalovirus-Specific CD4+ T Cells is Critical for Control of Virus Reactivation in Hematopoietic Stem Cell Transplant Recipients but Does Not Prevent Organ Infection.
Gabanti E; Lilleri D; Ripamonti F; Bruno F; Zelini P; Furione M; Colombo AA; Alessandrino EP; Gerna G
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2192-2202. PubMed ID: 26260678
[TBL] [Abstract][Full Text] [Related]
48. Antiviral treatment of cytomegalovirus infection.
Ahmed A
Infect Disord Drug Targets; 2011 Oct; 11(5):475-503. PubMed ID: 21827432
[TBL] [Abstract][Full Text] [Related]
49. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials.
Brennan DC; Legendre C; Patel D; Mange K; Wiland A; McCague K; Shihab FS
Am J Transplant; 2011 Nov; 11(11):2453-62. PubMed ID: 21812923
[TBL] [Abstract][Full Text] [Related]
50. Cytomegalovirus risk factors in renal transplantation with modern immunosuppression.
Bataille S; Moal V; Gaudart J; Indreies M; Purgus R; Dussol B; Zandotti C; Berland Y; Vacher-Coponat H
Transpl Infect Dis; 2010 Dec; 12(6):480-8. PubMed ID: 20629971
[TBL] [Abstract][Full Text] [Related]
51. New developments in the management of cytomegalovirus infection after solid organ transplantation.
Eid AJ; Razonable RR
Drugs; 2010 May; 70(8):965-81. PubMed ID: 20481654
[TBL] [Abstract][Full Text] [Related]
52. Inhibition of adenovirus transport from the endosome to the cell nucleus by rotenone.
Balsera-Manzanero M; Ghirga F; Ruiz-Molina A; Mori M; Pachón J; Botta B; Cordero E; Quaglio D; Sánchez-Céspedes J
Front Pharmacol; 2023; 14():1293296. PubMed ID: 38273842
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of Calcineurin or IMP Dehydrogenase Exerts Moderate to Potent Antiviral Activity against Norovirus Replication.
Dang W; Yin Y; Wang Y; Wang W; Su J; Sprengers D; van der Laan LJW; Felczak K; Pankiewicz KW; Chang KO; Koopmans MPG; Metselaar HJ; Peppelenbosch MP; Pan Q
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807916
[TBL] [Abstract][Full Text] [Related]
54. Clinical outcome in heart transplant recipients receiving everolimus in combination with dosage reduction of the calcineurin inhibitor cyclosporine A or tacrolimus.
Fuchs U; Zittermann A; Ensminger SM; Schulz U; Gummert JF
Transpl Immunol; 2014 Aug; 31(2):87-91. PubMed ID: 24932812
[TBL] [Abstract][Full Text] [Related]
55. A rapid quantitative PCR-based assay for testing antiviral agents against human adenoviruses demonstrates type specific differences in ribavirin activity.
Stock R; Harste G; Madisch I; Heim A
Antiviral Res; 2006 Oct; 72(1):34-41. PubMed ID: 16650905
[TBL] [Abstract][Full Text] [Related]
56. Nanotechnology against human cytomegalovirus in vitro: polyanionic carbosilane dendrimers as antiviral agents.
Relaño-Rodríguez I; Espinar-Buitrago MS; Martín-Cañadilla V; Gómez-Ramirez R; Jiménez JL; Muñoz-Fernández MA
J Nanobiotechnology; 2021 Mar; 19(1):65. PubMed ID: 33658029
[TBL] [Abstract][Full Text] [Related]
57. Adenovirus infection and disease in paediatric haematopoietic stem cell transplant patients: clues for antiviral pre-emptive treatment.
Feghoul L; Chevret S; Cuinet A; Dalle JH; Ouachée M; Yacouben K; Fahd M; Guérin-El Khourouj V; Roupret-Serzec J; Sterkers G; Baruchel A; Simon F; LeGoff J
Clin Microbiol Infect; 2015 Jul; 21(7):701-9. PubMed ID: 25882354
[TBL] [Abstract][Full Text] [Related]
58. [Immunology in clinical practice. VI. Current immunosuppressive drugs].
ten Berge RJ; Schellekens PT
Ned Tijdschr Geneeskd; 1997 Nov; 141(47):2289-92. PubMed ID: 9550813
[TBL] [Abstract][Full Text] [Related]
59. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
[TBL] [Abstract][Full Text] [Related]
60. In vitro assessment of the combined effect of letermovir and sirolimus on cytomegalovirus replication.
Giménez E; Guerreiro M; Gozalbo-Rovira R; Aguilar C; Albert E; Piñana JL; Solano C; Navarro D
Rev Esp Quimioter; 2023 Oct; 36(5):526-530. PubMed ID: 37365797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
